What is Rani Therapeutics Holdings Pre-Tax Income?
Pretax income is the income that a company earns before paying income taxes. Rani Therapeutics Holdings's pretax income for the
three
months ended in Dec. 2023 was $-14.06 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-67.88 Mil.
Rani Therapeutics Holdings's pretax margin was %.
During the past 5 years, Rani Therapeutics Holdings's highest Pretax Margin was -1952.41%. The lowest was -3607.79%. And the median was -2715.73%.
Rani Therapeutics Holdings Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Rani Therapeutics Holdings's Pre-Tax Income
For the Biotechnology subindustry, Rani Therapeutics Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's Pre-Tax Income falls into.
Rani Therapeutics Holdings Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings (NAS:RANI) Pre-Tax Income Explanation
Rani Therapeutics Holdings's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 5 years, Rani Therapeutics Holdings's highest Pretax Margin was -1952.41%. The lowest was -3607.79%. And the median was -2715.73%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rani Therapeutics Holdings Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Rani Therapeutics Holdings's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Rani Therapeutics Holdings (Rani Therapeutics Holdings) Business Description
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RANI has been successfully added to your 